Cite this: Apixaban Superior to Warfarin Across Range of INR Values: ARISTOTLE Analysis - Medscape - May 08, 2013. References. Authors and Disclosures. Authors and Disclosures Journalist ...

In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial ...

Results from ARISTOTLE also demonstrated that ELIQUIS was superior to warfarin for the primary safety outcome of ISTH major bleeding (p<0.001), yielding a significant relative risk reduction of 31 ...

A large-scale trial finds that apixaban, a new anticoagulant drug, ... Apixaban Superior To Warfarin In Preventing Stroke. by VR Sreeraman on August 28, 2011 at 4:21 PM. Facebook; ...

The benefits of apixaban on stroke/systemic embolism and all-cause death vs. warfarin are similar in patients with and without peripheral artery disease (PAD), but a greater reduction in bleeding ...

Apixaban Superiority Holds Up Across Range of Warfarin INR Control In a substudy bolstering the main findings, Lars C. Wallentin, MD, PhD, of the Uppsala Clinical Research Center (Uppsala, Sweden), ...

Eliquis was consistent in reducing the risk of stroke or systemic embolism versus warfarin in patients with and without poor blood pressure control during the trial (p for interaction = 0.97).1 ...

The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and ...

Lackluster Findings for Warfarin. Bea and colleagues used Medicare and two commercial insurance databases for the analysis of 163,593 patients (mean age 71.4 years; 56.7% women) who initiated an oral ...

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death ELIQUIS, Compared to Standard of Care Warfarin, Significantly Reduced:Risk of stroke or ...